Neumora Therapeutics Inc

NASDAQ:NMRAUnited States

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Contact Information

Headquarters

490 Arsenal Way, Suite 200WATERTOWN, MA, United States 02472

Phone

857-760-0900

Fax

302-655-5049

Executives

Executive Chairman of the Board, Co-Founder

Paul Berns

President, Chief Executive Officer, Director

Henry Gosebruch

Co-Founder, Chief Operating Officer

Carol Suh

Chief Financial Officer

Joshua Pinto

Chief Strategy Officer

Daljit Aurora